<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id>
      <journal-title-group>
        <journal-title>BMC Nephrology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2369</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21651778</article-id>
      <article-id pub-id-type="pmc">3127995</article-id>
      <article-id pub-id-type="publisher-id">1471-2369-12-26</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2369-12-26</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anti-hLAMP2-antibodies and dual positivity for anti-GBM and MPO-ANCA in a patient with relapsing pulmonary-renal syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Etter</surname>
            <given-names>Christoph</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>christoph.etter@web.de</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Gaspert</surname>
            <given-names>Ariana</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>ariana.gaspert@usz.ch</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Regenass</surname>
            <given-names>Stephan</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>stephan.regenass@usz.ch</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>W&#xFC;thrich</surname>
            <given-names>Rudolf P</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>rudolf.wuethrich@usz.ch</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Kistler</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>thomas.kistler@ksw.ch</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Kain</surname>
            <given-names>Renate</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>renate.kain@meduniwien.ac.at</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A7">
          <name>
            <surname>Cohen</surname>
            <given-names>Clemens D</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>clemens.cohen@usz.ch</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of Nephrology, University Hospital Zurich, Zurich, Switzerland</aff>
      <aff id="I2"><label>2</label>Institute of Physiology, University of Zurich, Zurich, Switzerland</aff>
      <aff id="I3"><label>3</label>Department of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland</aff>
      <aff id="I4"><label>4</label>Division of Clinical Immunology, University Hospital Zurich, Zurich, Switzerland</aff>
      <aff id="I5"><label>5</label>Division of Nephrology, Kantonsspital Winterthur, Winterthur, Switzerland</aff>
      <aff id="I6"><label>6</label>Department of Pathology, Medical University of Vienna, Vienna, Austria</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <volume>12</volume>
      <fpage>26</fpage>
      <lpage>26</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>6</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Etter et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Etter et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2369/12/26"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Pulmonary-renal syndrome associated with anti-glomerular basement membrane (GBM) antibodies, also known as Goodpasture's syndrome, is a rare but acute and life-threatening condition. One third of patients presenting as anti-GBM antibody positive pulmonary-renal syndrome or rapidly progressive glomerulonephritis are also tested positive for anti-neutrophil cytoplasmic antibodies (ANCA). Whilst anti-GBM disease is considered a non-relapsing condition, the long-term course of double-positive patients is less predictable.</p>
        </sec>
        <sec>
          <title>Case Presentation</title>
          <p>We report a patient with such dual positivity, who presented with pulmonary hemorrhage, crescentic glomerulonephritis and membranous nephropathy. Plasmapheresis in combination with immunosuppresive therapy led to a rapid remission but the disease relapsed after two years. The serum of the patient was tested positive for antibodies to human lysosomal membrane protein 2 (hLAMP2), a novel autoantigen in patients with active small-vessel vasculitis (SVV). The anti-hLAMP2 antibody levels correlated positively with clinical disease activity in this patient.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>We hypothesize that this antibody may indicate a clinical course similar to ANCA-associated vasculitis in double-positive patients. However, this needs to be confirmed on comprehensive patient cohorts.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Anti-GBM disease, also known as Goodpasture's syndrome, is a paradigm for an autoimmune disease: The antigenic epitope in the non-collagenous region of the alpha 3 chain of type IV collagen [&#x3B1;3(IV)NC1] is well defined, and the confined expression of this collagen to glomerular and alveolar basement membranes leads to the organ specificity of the disease [<xref ref-type="bibr" rid="B1">1</xref>]. In renal biopsies linear positivity for immunoglobulin G (IgG) along the GBM indicates the direct pathogenetic relevance of the antibody. Interestingly, up to a third of patients with anti-GBM disease are also positive for ANCA, mainly with specificity to myeloperoxidase (MPO) [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. This latter antibody is commonly associated with microscopic polyangiitis and to a lesser extent with granulomatosis with polyangiitis (Wegener's). Both are ANCA-positive SVV with frequent renal involvement as crescentic glomerulonephritis without prominent Ig deposition (pauci-immune CGN). The relatively high incidence of such dual positivity indicates a pathogenetic link, which still has to be unravelled. It is tempting to speculate on ANCA-associated mechanisms leading to the exposure of the otherwise hidden GBM-antigen [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Some reports on a sequential positivity of ANCA followed by anti-GBM antibodies support this hypothesis but other reports also describe the opposite sequence [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Controversies exist on the course of disease of double-positive patients. Older studies reported a favourable course [<xref ref-type="bibr" rid="B10">10</xref>] but more recent reports conclude that renal prognosis is comparable to anti-GBM disease [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Whilst anti-GBM disease is generally considered a non-relapsing illness, ANCA-positive SVV has a relevant risk of relapses demanding maintenance therapy after induction of remission [<xref ref-type="bibr" rid="B12">12</xref>]. In double-positive patients both relapsing and non-relapsing courses of disease can be observed [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Therefore, an indicator for relapsing disease in double-positive patients is awaited.</p>
      <p>This report summarizes our experience on diagnosis and treatment of a patient with pulmonary-renal syndrome (PRS), relapsing CGN with subepithelial immune deposits and serological dual positivity for both anti-GBM antibodies and MPO-ANCA, who was also tested positive for novel SVV-associated antibodies against hLAMP2.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A non-smoking, 52-year-old woman presented to her general practitioner with headache, fever and right-sided thoracic pain. The chest radiograph showed a pulmonary infiltrate of the right lower lobe. Antibiotic therapy was initiated. Due to persistent fever a chest computed tomography (CT) was performed two weeks later, which showed low grade but diffuse ground-glass infiltration beside previously described bronchiectasis. Alveolar hemorrhage was documented by bronchoscopy. The histologic examination of a lung biopsy showed alveolar siderophages and focal chronic lymphocytic infiltration; no immunofluorescence was performed. Consecutive decline of kidney function completed the clinical picture of a PRS and the patient was referred to a renal division. Laboratory values at the time of referral are given in Table <xref ref-type="table" rid="T1">1</xref>. The serum tested positive for anti-GBM antibodies as well as ANCA by standard indirect immunofluorescence (ANA negative, anti-dsDNA 6 E/ml (normal &lt; 20)). Subsequent tests revealed antibody reactivity against both, MPO and NC1 domain of type IV collagen. A renal biopsy was performed and documented a necrotizing extracapillary proliferative glomerulonephritis. There were nine glomeruli, one hyalinized, with five mostly segmental crescents (two cellular, three fibrocellular). A less well-preserved, frozen biopsy specimen did not show linear staining for human IgG by direct immunofluorescence. Similarly, all other immunoglobulins and complement factors were negative (IgA, IgM, Kappa, Lambda, C3, C1q). This was surprising since electron microscopy revealed small subepithelial deposits of a membranous nephropathy stage 1, without subendothelial or mesangial deposits (Figure <xref ref-type="fig" rid="F1">1</xref>, see legend for details). The co-occurance of CGN and membranous nephropathy is rare but has been described in detail previously [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Laboratory results at initial presentation (month -1), admission to hospital (month 0, time of first renal biopsy), remission (month 1, 6, 12, 18), first relapse (month 23, time of second renal biopsy), and under therapy (month 25)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left">Time (months)</th>
              <th align="center">-1</th>
              <th align="center">0</th>
              <th align="center">1</th>
              <th align="center">6</th>
              <th align="center">12</th>
              <th align="center">18</th>
              <th align="center">23</th>
              <th align="center">25</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">
                <bold>Renal Biopsy (no.)</bold>
              </td>
              <td/>
              <td align="center">
                <bold>1</bold>
              </td>
              <td/>
              <td/>
              <td/>
              <td/>
              <td align="center">
                <bold>2</bold>
              </td>
              <td/>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">Hemoglobin [11.7 - 15.3 g/dl]</td>
              <td align="center">9.4</td>
              <td align="center">
                <bold>8.7</bold>
              </td>
              <td align="center">9.2</td>
              <td align="center">11.7</td>
              <td align="center">12.6</td>
              <td align="center">14.1</td>
              <td align="center">
                <bold>11</bold>
              </td>
              <td align="center">12.9</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">C-reactive protein [&lt; 5 mg/l]</td>
              <td align="center">84</td>
              <td align="center">
                <bold>13</bold>
              </td>
              <td align="center">2</td>
              <td align="center">&lt; 3</td>
              <td align="center">&lt; 3</td>
              <td align="center">&lt; 3</td>
              <td align="center">
                <bold>&lt; 3</bold>
              </td>
              <td align="center">&lt; 3</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">Creatinine [44 - 80 &#x3BC;mol/l]</td>
              <td align="center">121</td>
              <td align="center">
                <bold>428</bold>
              </td>
              <td align="center">172</td>
              <td align="center">105</td>
              <td align="center">97</td>
              <td align="center">106</td>
              <td align="center">
                <bold>165</bold>
              </td>
              <td align="center">136</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">eGFR [&gt; 60 ml/min]</td>
              <td align="center">41</td>
              <td align="center">
                <bold>10</bold>
              </td>
              <td align="center">27</td>
              <td align="center">48</td>
              <td align="center">53</td>
              <td align="center">48</td>
              <td align="center">
                <bold>29</bold>
              </td>
              <td align="center">35</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">Proteinuria [&lt; 150 mg/d]</td>
              <td align="center">n.a.</td>
              <td align="center">
                <bold>1700</bold>
              </td>
              <td align="center">n.a.</td>
              <td align="center">130</td>
              <td align="center">110</td>
              <td align="center">139</td>
              <td align="center">
                <bold>590</bold>
              </td>
              <td align="center">230</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">MPO-ANCA [&lt; 5 units/ml]</td>
              <td align="center">121</td>
              <td align="center">
                <bold>58</bold>
              </td>
              <td align="center">7</td>
              <td align="center">8</td>
              <td align="center">13</td>
              <td align="center">19</td>
              <td align="center">
                <bold>53</bold>
              </td>
              <td align="center">10</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">Anti-GBM [&lt; 10 units/ml]</td>
              <td align="center">130</td>
              <td align="center">
                <bold>68</bold>
              </td>
              <td align="center">9</td>
              <td align="center">2</td>
              <td align="center">n.a.</td>
              <td align="center">n.a.</td>
              <td align="center">
                <bold>23</bold>
              </td>
              <td align="center">7</td>
            </tr>
            <tr>
              <td colspan="9">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">hLAMP-2 [units, see legend]</td>
              <td align="center">n.a.</td>
              <td align="center"><bold>n.a</bold>.</td>
              <td align="center">2</td>
              <td align="center">23</td>
              <td align="center">20</td>
              <td align="center">20</td>
              <td align="center">
                <bold>31</bold>
              </td>
              <td align="center">19</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Normal values and units are given in squared bracket. eGFR = estimated glomerular filtration rate according to MDRD formula, n.a. = not available.</p>
          <p>For detection of hLAMP-2 antibodies archival sera for different time-points were assayed. Briefly, the ELISA used human recombinant extracellular domain expressed in E. coli as substrate and the results were expressed as units derived from standard curve of a single strongly positive serum (negative &lt; 22, possible 22 - 28, positive &gt; 28)</p>
        </table-wrap-foot>
      </table-wrap>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Renal biopsy findings</bold>. The first biopsy (corresponding to month 0 in table 1) showed cellular crescents (A) in two and fibrocellular crescents (B) in three out of nine glomeruli, consistent with crescentic glomerulonephritis with moderate activity and moderate chronicity (Silver methenamine stain; original magnification, (A) &#xD7;200, (B) &#xD7;180). The glomerular basement membrane revealed multiple small holes, no spikes. Immunofluorescence study results were negative but on electron microscopy multiple small subepithelial deposits (arrows) indicative of membranous nephropathy stage 1 were visible (C, original magnification, &#xD7;10.500). In the second biopsy (corresponding to month 23 in table 1) widespread global sclerosis was present with sclerosis of 15 of 32 glomeruli and crescents in 5 glomeruli: two segmental fibrous crescents, two fibrocellular (one gobal (arrow in D)), one segmental cellular crescent, with focal interstitial fibrosis and tubular atrophy, comprising 25% of the cortex, consistent with late ANCA-associated sclerosing glomerulonephritis with minimal activity and severe chronicity (Silver methenamine stain; original magnification, (D) &#xD7;50, (E) &#xD7;160). Immunofluorescence studies showed finely granular glomerular basement membrane positivity for IgG (2+) corresponding to the previously diagnosed membranous nephropathy and a segmental linear (arrows) GBM positivity (F original magnification, &#xD7;280).</p>
        </caption>
        <graphic xlink:href="1471-2369-12-26-1"/>
      </fig>
      <p>We concluded that the patient had double-positive Goodpasture's syndrome with falsely negative immunofluorescence due to a not perfectly preserved frozen biopsy specimen. Induction therapy was established with plasma exchange, pulse cyclophosphamide and prednisone [<xref ref-type="bibr" rid="B12">12</xref>]. Anti-GBM titers became negative, MPO-ANCA fell to 8 E/ml (normal &lt; 5; Table <xref ref-type="table" rid="T1">1</xref>). Cyclophosphamide was stopped after three months but we decided to pursue with maintenance therapy with azathioprine because of the aforementioned findings also consistent with SVV. However, on demand of the patient prednisone was rapidly tapered and azathioprine stopped after 15 months. Kidney function had recovered to an estimated glomerular filtration rate of 50 ml/min. Seven months after discontinuation of the maintenance therapy the patient presented with mild dyspnea and worsening kidney function as well as proteinuria and microhematuria with dysmorphic erythrocytes. Anti-GBM antibodies were found to be positive again (28 E/ml) and rising MPO-ANCA were detected (56 E/ml, Table <xref ref-type="table" rid="T1">1</xref>). An initial chest CT showed regressive diffuse small pulmonary infiltration, but no signs of acute pulmonary hemorrhage. For the second time a kidney biopsy was performed and showed a mostly global sclerosing but also extracapillary proliferative glomerulonephritis again in combination with a membranous nephropathy (detailed in the legend of Figure <xref ref-type="fig" rid="F2">2</xref>). Focal interstitial fibrosis and tubular atrophy was also observed. A global finely granular and a discreet segmental linear IgG positivity was detected by immunofluorescence in the GBM (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Detection of anti-hLAMP2 antibodies</bold>. A. The patient's serum at time of relapse (month 23) was tested positive by indirect immunfluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface; whereas only minor staining was obtained during remission (month 6). Results of the serum from a healthy, negative control and a positive SVV-control are shown in picture 1 and 2, respectively. B. The serum was also tested positive by Western blot on E. coli expressed fusion protein. Lane 1-6: Serum of our patient at different time-points (one major band corresponding to the fusion protein at around 66 kD). Lane 7: rabbit anti-hLAMP-2 polyclonal serum (positive control). Lane 8: anti-human (negative control). All methods for detection of hLAMP-2 antibodies are published in detail elsewhere [<xref ref-type="bibr" rid="B15">15</xref>].</p>
        </caption>
        <graphic xlink:href="1471-2369-12-26-2"/>
      </fig>
      <p>As this patient presented with the rare combination of dual positivity for anti-GBM and MPO-ANCA with relapsing pauci-immune CGN we examined the serum at time of relapse for anti-hLAMP2 antibodies, a new class of antibodies associated with SVV [<xref ref-type="bibr" rid="B15">15</xref>]. The serum was indeed tested positive for anti-hLAMP2 antibodies. This prompted us to test also archival serum samples of this patient by enzyme-linked immunosorbent assay (ELISA), immunfluorescence on cells stably expressing hLAMP2 on the cell surface, and western blot (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). The serum concentration of anti-hLAMP2 antibodies correlated positively with disease activity (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). The lack of the typical intense global linear IgG staining of the glomeruli combined with rising antibody titers to MPO together with the presence of anti-hLAMP2 antibodies led us to judge the disease as relapsing ANCA-associated SVV; hence plasmapheresis was discontinued and cyclophosphamide with prednisone successfully reintroduced.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>So far, no conclusive maintenance therapy for patients with dual antibody specificity for NC1 and MPO has been established. This is at least in part due to the lack of understanding the sequential events leading to the development of both antibody types but, more importantly, due to failure to identify the disease defining antibody that will, ultimately, determine progression and outcome. Anti-hLAMP2 antibodies appear to indicate active SVV and may thus serve as an indicator for relapsing disease also in patients with dual positivity. This antibody reacts with an antigen expressed on endothelial cells and neutrophils that shares complete homology to the bacterial adhesin FimH [<xref ref-type="bibr" rid="B15">15</xref>]. It is reported to be present in 90% of cases with active phases of ANCA-associated necrotizing and crescentic glomerulonephritis and was also seen in a small proportion of patients with ANCA-positive Goodpasture's syndrome [<xref ref-type="bibr" rid="B15">15</xref>].</p>
      <p>Several characteristics of this patient led us to test her serum for anti-hLAMP2 antibodies: First, Goodpasture's syndrome is considered a non-relapsing disease [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In this patient the disease relapsed after a clinical and serological remission. Second, two findings in the renal biopsies are also suggestive for a SVV-like disease: The initial biopsy did reveal different ages of glomerular lesions (cellular and fibrocellular crescents, detailed in the legend of Figure <xref ref-type="fig" rid="F1">1</xref>). This indicates a continuously evolving glomerulonephritis and not a sudden and defined initiation. Such diverse glomerular alterations are less common in acute anti-GBM disease [<xref ref-type="bibr" rid="B16">16</xref>]. The immunofluorescence of the initial kidney biopsy was not positive and the subsequent biopsy showed mostly a granular positivity for IgG corresponding to the membranous nephropathy and only a segmental and not the intense global linear positivity for IgG as in typical anti-GBM disease. In the literature most authors report strong linear positivity for IgG in double-positive patients [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>], although a scanty positivity has also been described in a subset of patients [<xref ref-type="bibr" rid="B3">3</xref>]. The membranous nephropathy is another interesting aspect in our patient. Although glomerular immune deposits are found in about 50% of ANCA-associated CGN an isolated subepithelial localisation of the immune complex deposits is rarely observed. If present the combination of membranous nephropathy and CGN appears to be associated with high proteinuria and may accentuate the clinical course of CGN [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p>We concluded that the clinical course and the histology results are more suggestive for SVV than anti-GBM disease. This SVV-like course of disease can be seen in conjunction with the positivity for anti-hLAMP2 antibodies. One may hypothesize that the primary event is SVV with glomerular and alveolar damage and subsequent development of anti-GBM antibodies. However, this can only be tested on serial serum samples taken before disease manifestation and cannot be concluded from a case-report.</p>
      <p>This case highlights the importance of testing for coexistence of different antibodies in patients with PRS, as it may be a common manifestation of both SVV and Goodpasture's disease [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. However, since the best long-term treatment of double-positive patients is unknown, an indicator for a relapsing SVV-like course of disease would be helpful. Our case and its interpretation suggest that anti-hLAMP2 antibodies may indicate a SVV-like course of disease and therefore could be of clinical utility for the management of double-positive patients. However, this needs to be tested on adequate patient cohorts.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>List of abbreviations</title>
      <p>ANCA: anti-neutrophil cytoplasmic antibodies; CGN: crescentic glomerulonephritis; CT: computed tomography; GBM: glomerular basement membrane; hLAMP2: human lysosomal membrane protein 2; IgG: immunoglobulin G; MPO: myeloperoxidase; PRS: pulmonary-renal syndrome; SVV: small-vessel vasculitis</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>AG interpreted the kidney biopsies and wrote the corresponding legend. SR analyzed the patient's serum for presence and specificity of ANCA and anti-GBM antibodies. TK first treated the patient and provided data about the history and laboratory results. RK analyzed the patient's serum for presence of anti-hLAMP2 antibodies and contributed to the manuscript. CE and CDC treated the patient, collected data and sera, and drafted the manuscript together with RPW. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2369/12/26/prepub">http://www.biomedcentral.com/1471-2369/12/26/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hudson</surname>
            <given-names>BG</given-names>
          </name>
          <name>
            <surname>Tryggvason</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sundaramoorthy</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Neilson</surname>
            <given-names>EG</given-names>
          </name>
          <article-title>Alport's syndrome, Goodpasture's syndrome, and type IV collagen</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <fpage>2543</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra022296</pub-id>
          <pub-id pub-id-type="pmid">12815141</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Levy</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Hammad</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Coulthart</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dougan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Pusey</surname>
            <given-names>CD</given-names>
          </name>
          <article-title>Clinical features and outcome of patients with both ANCA and anti-GBM antibodies</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>66</volume>
          <fpage>1535</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00917.x</pub-id>
          <pub-id pub-id-type="pmid">15458448</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rutgers</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Slot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>van Paassen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>van Breda Vriesman</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Heeringa</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tervaert</surname>
            <given-names>JW</given-names>
          </name>
          <article-title>Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis</article-title>
          <source>Am J Kidney Dis</source>
          <year>2005</year>
          <volume>46</volume>
          <fpage>253</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2005.05.003</pub-id>
          <pub-id pub-id-type="pmid">16112043</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hellmark</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Segelmark</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>HY</given-names>
          </name>
          <article-title>Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>1338</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1681/ASN.2006111210</pub-id>
          <pub-id pub-id-type="pmid">17329569</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lionaki</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jennette</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Falk</surname>
            <given-names>RJ</given-names>
          </name>
          <article-title>Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis</article-title>
          <source>Semin Immunopathol</source>
          <year>2007</year>
          <volume>29</volume>
          <fpage>459</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1007/s00281-007-0093-0</pub-id>
          <pub-id pub-id-type="pmid">17943286</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lindic</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Vizjak</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ferluga</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kovac</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ales</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kveder</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ponikvar</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bren</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane</article-title>
          <source>Ther Apher Dial</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>278</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1744-9987.2009.00724.x</pub-id>
          <pub-id pub-id-type="pmid">19695059</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hellmark</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Niles</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>AB</given-names>
          </name>
          <name>
            <surname>McCluskey</surname>
            <given-names>RT</given-names>
          </name>
          <name>
            <surname>Brunmark</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Comparison of anti-GBM antibodies in sera with or without ANCA</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1997</year>
          <volume>8</volume>
          <fpage>376</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">9071706</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Peces</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rodriguez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pobes</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Seco</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Sequential development of pulmonary hemorrhage with MPO-ANCA complicating anti-glomerular basement membrane antibody-mediated glomerulonephritis</article-title>
          <source>Am J Kidney Dis</source>
          <year>2000</year>
          <volume>35</volume>
          <fpage>954</fpage>
          <lpage>957</lpage>
          <pub-id pub-id-type="doi">10.1016/S0272-6386(00)70269-1</pub-id>
          <pub-id pub-id-type="pmid">10793033</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Serratrice</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chiche</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dussol</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Granel</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Daniel</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Jego-Desplat</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Disdier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Swiader</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Berland</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Weiller</surname>
            <given-names>PJ</given-names>
          </name>
          <article-title>Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis</article-title>
          <source>Am J Kidney Dis</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>e26</fpage>
          <lpage>e30</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2003.11.019</pub-id>
          <pub-id pub-id-type="pmid">14981638</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bosch</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Mirapeix</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Font</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Borrellas</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Rodr&#xED;guez</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>L&#xF3;pez-Soto</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ingelmo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Revert</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease</article-title>
          <source>Clin Nephrol</source>
          <year>1991</year>
          <volume>36</volume>
          <fpage>107</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">1657470</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Levy</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>AN</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Pusey</surname>
            <given-names>CD</given-names>
          </name>
          <article-title>Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression</article-title>
          <source>Ann Intern Med</source>
          <year>2001</year>
          <volume>134</volume>
          <fpage>1033</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">11388816</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mukhtyar</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Guillevin</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cid</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Dasgupta</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>de Groot</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Hauser</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hellmich</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jayne</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kallenberg</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Merkel</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Raspe</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Salvarani</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Stegeman</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Watts</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Westman</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Witter</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yazici</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Luqmani</surname>
            <given-names>R</given-names>
          </name>
          <collab>European Vasculitis Study Group</collab>
          <article-title>EULAR recommendations for the management of primary small and medium vessel vasculitis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2009</year>
          <volume>68</volume>
          <fpage>310</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2008.088096</pub-id>
          <pub-id pub-id-type="pmid">18413444</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Haas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Eustace</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>65</volume>
          <fpage>2145</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00632.x</pub-id>
          <pub-id pub-id-type="pmid">15149327</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nasr</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Said</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Valeri</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Stokes</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Masani</surname>
            <given-names>NN</given-names>
          </name>
          <name>
            <surname>D'Agati</surname>
            <given-names>VD</given-names>
          </name>
          <name>
            <surname>Markowitz</surname>
            <given-names>GS</given-names>
          </name>
          <article-title>Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>299</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.2215/CJN.04060808</pub-id>
          <pub-id pub-id-type="pmid">19158367</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kain</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Exner</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brandes</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ziebermayr</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cunningham</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Alderson</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Davidovits</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Raab</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Jahn</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ashour</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Spitzauer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sunder-Plassmann</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Klemm</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Kerjaschki</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis</article-title>
          <source>Nat Med</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>1088</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.1874</pub-id>
          <pub-id pub-id-type="pmid">18836458</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kluth</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>AJ</given-names>
          </name>
          <article-title>Anti-glomerular basement membrane disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1999</year>
          <volume>10</volume>
          <fpage>2446</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">10541306</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sinclair</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Stevens</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides</article-title>
          <source>Ann Clin Biochem</source>
          <year>2007</year>
          <volume>44</volume>
          <fpage>432</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1258/000456307781646049</pub-id>
          <pub-id pub-id-type="pmid">17761028</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
